Form 4 for ATYR aTYR PHARMA INC
Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-05 · accession 0001209191-24-002949 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-06 | 2024-02-05 | ATYR | Shukla Sanjay | Pres, CEO, Dir | M - OptEx | — | +10.4K | 116.5K | +10% | — |
| D | 2024-02-06 | 2024-02-05 | ATYR | Shukla Sanjay | Pres, CEO, Dir | M - OptEx | $0.00 | -10.4K | 20.8K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2024-02-05 | M | A | 10,375 | — | 116,548 | D | — | — | (F2) Restricted stock units convert into common stock on a one-for-one basis. |
| 2 | Derivative | Restricted Stock Unit | 2024-02-05 | M | D | 10,375 | $0.00 | 20,750 | D | — · — to — | 10,375 Common Stock | (F2) Restricted stock units convert into common stock on a one-for-one basis. (F3) The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |